Drugs / JADE101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07525947 | May 2026 → May 2027 expected | — | Jade Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07059312 | Aug 2025 → Oct 2026 expected | — | Jade Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07541287 | May 2026 → Jan 2029 expected | IgA glomerulonephritis | Jade Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JADE101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07541287 ↗ |
| Route | Subcutaneous | “administered by SC injection” NCT07059312 ↗ |